| Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript |
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Anish Bhatnagar - Chief Executive Officer Meredith Manning - Chief Commercial Officer Jim Mackaness - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Debjit Chattopadhyay - Guggenheim Securities Kristen Kluska - Cantor Leland Gershell - Oppenheimer Brian Skorney - Baird James Condulis - Stifel Myriam Belghiti - LifeSci Capital Yale Jen - Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-08 02:30:35 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results |
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable |
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2025-05-06 13:50:30 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET |
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. |
globenewswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces VYKAT(TM) XR Launch |
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025. |
globenewswire.com |
2025-04-14 11:00:00 |
Czytaj oryginał (ang.) |
| SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug |
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients. |
zacks.com |
2025-03-27 11:50:35 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder |
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). |
benzinga.com |
2025-03-27 10:11:22 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome |
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). |
globenewswire.com |
2025-03-26 19:15:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics to Participate in Upcoming February Investor Conferences |
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February: |
globenewswire.com |
2025-01-29 18:05:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC |
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million. |
globenewswire.com |
2024-12-17 18:05:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference |
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. |
globenewswire.com |
2024-11-27 10:00:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome |
REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. |
globenewswire.com |
2024-11-26 10:30:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 |
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. |
globenewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments |
Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects. |
seekingalpha.com |
2024-10-10 18:53:48 |
Czytaj oryginał (ang.) |
| SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA |
Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS. |
zacks.com |
2024-10-09 14:35:26 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's Why |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-10-09 13:50:35 |
Czytaj oryginał (ang.) |
| SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval |
Soleno Therapeutics (SLNO, Financial) experienced a notable stock price increase of 9.11% following positive developments in its regulatory process. This performance far exceeded that of the S&P 500 index, which saw gains of less than 1%. |
gurufocus.com |
2024-10-08 22:51:58 |
Czytaj oryginał (ang.) |
| Why Soleno Therapeutics Stock Blasted 9% Higher Today |
The company's Prader-Willi treatment inched closer to FDA approval. |
fool.com |
2024-10-08 22:29:00 |
Czytaj oryginał (ang.) |
| Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc |
On September 30, 2024, Janus Henderson Group PLC, a prominent investment firm, significantly increased its stake in Soleno Therapeutics Inc (SLNO, Financial) by acquiring an additional 804,805 shares. This transaction, executed at a price of $50.49 per share, has raised the firm's total holdings in Soleno to 4,163,678 shares. |
gurufocus.com |
2024-10-03 16:03:43 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference |
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time. |
globenewswire.com |
2024-09-16 20:05:00 |
Czytaj oryginał (ang.) |
| Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review |
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review. |
zacks.com |
2024-08-28 15:25:30 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients |
Soleno Therapeutics, Inc.'s NDA submission of DCCR for the treatment of patients with PWS accepted by the FDA with Priority Review with a PDUFA date of December 27th of 2024. Before the FDA PDUFA date of DCCR for the treatment of patients with PWS, the FDA plans to hold an advisory panel meeting for this drug. If DCCR is granted U.S. marketing approval, it would be the first approved drug of its kind to target hyperphagia and some other problems associated with PWS. |
seekingalpha.com |
2024-08-27 17:00:49 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome |
PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for DCCR for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. |
globenewswire.com |
2024-08-27 12:00:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees. |
globenewswire.com |
2024-08-19 20:17:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome |
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. |
globenewswire.com |
2024-06-28 12:00:00 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to eight new employees. |
globenewswire.com |
2024-06-24 21:18:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Long-Term Investors to Contact the Firm |
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) ("Soleno") on behalf of the company's stockholders. The investigation seeks to determine whether Soleno and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions. |
accesswire.com |
2024-06-11 17:00:00 |
Czytaj oryginał (ang.) |
| 3 Stocks That Have Seen Higher Share Gains Than Super Micro Computer |
One of the stocks to benefit the most from the artificial intelligence (AI) craze has been Super Micro Computer (Nasdaq: SMCI). |
247wallst.com |
2024-06-06 20:18:05 |
Czytaj oryginał (ang.) |
| Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 |
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts. |
globenewswire.com |
2024-05-22 20:05:00 |
Czytaj oryginał (ang.) |